ExpreS2ion Biotech: Rights issue outcome – SEK31.8m raised - Redeye

Redeye comments on the announced outcome of ExpreS2ion’s recent rights issue, which was subscribed to ~60% including guarantors and will provide gross proceeds of SEK31.8m. While the financing strengthens near-term funding and supports continued progress of ES2B-C001, the lower-than-expected subscription implies a tighter cash runway and continued reliance on future funding.

Länk till analysen i sin helhet: https://www.redeye.se/research/1164266/expres2ion-biotech-rights-issue-outcome-sek31-8m-raised?utm_source=finwire&utm_medium=RSS